Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Muscle-invasive and advanced bladder cancer, drawn from the whole corpus: 49 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Cisplatin-ineligible patients still have fewer options.
Choosing between cystectomy and bladder preservation lacks randomised evidence.
Variant histologies are excluded from most trials.
Cost and access to antibody-drug conjugates.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
High-risk NMIBC with BCG
EFS HR 0.
A milestone in how this cancer is treated.
OS HR 0.
A milestone in how this cancer is treated.